PREMIER ANTI-AGING CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 921 JPY | -0.75% |
|
+6.11% | -8.90% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Personal Products
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -8.90% | 50.31M | - | ||
| -7.83% | 235B | B- | ||
| 0.00% | 19.58B | - | - | |
| +11.57% | 18.85B | B+ | ||
| +8.42% | 11.4B | A- | ||
| -18.32% | 8.65B | A- | ||
| +15.38% | 7.45B | B+ | ||
| +11.66% | 6.03B | B | ||
| -6.93% | 3.87B | B+ | ||
| -17.09% | 3.72B | C- |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 4934 Stock
- Ratings Premier Anti-Aging Co., Ltd.
